{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:43:37Z","timestamp":1790401417101,"version":"4.1.0"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"DOI":"10.3389\/fcell.2020.00546","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T05:49:35Z","timestamp":1594360175000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential"],"prefix":"10.3389","volume":"8","author":[{"given":"Alexandre","family":"Perla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00edvia","family":"Fratini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula S.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"N\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 T.","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Algemir L.","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Brunetto","family":"de Farias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Roesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004482","article-title":"Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.","volume":"4","author":"Algar","year":"2009","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7610","DOI":"10.1007\/s12035-016-0250-3","article-title":"Combined treatments with a retinoid receptor agonist and epigenetic modulators in human neuroblastoma cells.","volume":"54","author":"Almeida","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"B3","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccell.2019.09.005","article-title":"Re-programing chromatin with a bifunctional LSD1\/HDAC inhibitor induces therapeutic differentiation in DIPG.","volume":"36","author":"Anastas","year":"2019","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrg.2017.57","article-title":"The interplay of epigenetic marks during stem cell differentiation and development.","volume":"18","author":"Atlasi","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101530","article-title":"Epigenetic drugs for cancer and microRNAs: a focus on histone deacetylase inhibitors.","volume":"11","author":"Autin","year":"2019","journal-title":"Cancers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1242\/dev.162693","article-title":"The developmental origin of brain tumours: a cellular and molecular framework.","volume":"145","author":"Azzarelli","year":"2018","journal-title":"Development"},{"key":"B7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10555-019-09840-2","article-title":"Drug repurposing towards targeting cancer stem cells in pediatric brain tumors.","volume":"39","author":"Bahmad","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/jclinpath-2019-206246","article-title":"Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets.","volume":"73","author":"Bahmad","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah6904","article-title":"Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.","volume":"8","author":"Bayliss","year":"2016","journal-title":"Sci. Transl. Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03535-3","article-title":"Epigenetics and survivorship in pediatric brain tumor patients.","author":"Bhattacharya","year":"2020","journal-title":"J. Neurooncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.cell.2013.06.051","article-title":"KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors.","volume":"154","author":"Black","year":"2013","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00066-011-0028-5","article-title":"Suberoylanilide hydroxamic acid affects \u03b3H2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.","volume":"188","author":"Blattmann","year":"2012","journal-title":"Strahlenther. Onkol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors.","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"B14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.2936","article-title":"Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.","volume":"46","author":"Buczkowicz","year":"2014","journal-title":"Nat. Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2013","article-title":"Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation.","volume":"12","author":"Canettieri","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"38879","DOI":"10.1074\/jbc.m505733200","article-title":"Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes.","volume":"280","author":"Chen","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.canlet.2018.10.012","article-title":"Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.","volume":"442","author":"Choi","year":"2019","journal-title":"Cancer Lett."},{"key":"B18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1593\/neo.101630","article-title":"Identification and characterization of KCASH2 and KCASH3, 2 novel Cullin3 adaptors suppressing histone deacetylase and Hedgehog activity in medulloblastoma.","volume":"13","author":"De Smaele","year":"2011","journal-title":"Neoplasia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/1535-7163.mct-14-0481","article-title":"Histone deacetylase 6 represents a novel drug target in the oncogenic Hedgehog signaling pathway.","volume":"14","author":"Dhanyamraju","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coph.2019.11.007","article-title":"Histone deacetylases 1, 2 and 3 in nervous system development.","volume":"50","author":"D\u2019Mello","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-1-61779-612-8_8","article-title":"The epigenetics of brain tumors.","volume":"863","author":"Dubuc","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-015-0201-7","article-title":"Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.","volume":"3","author":"Ecker","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"B23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ccell.2018.11.014","article-title":"Comprehensive analysis of chromatin states in atypical teratoid\/rhabdoid tumor identifies diverging roles for SWI\/SNF and polycomb in gene regulation.","volume":"35","author":"Erkek","year":"2019","journal-title":"Cancer Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1038\/emboj.2008.172","article-title":"Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells.","volume":"27","author":"Ferretti","year":"2008","journal-title":"EMBO J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1200\/jco.2009.25.9119","article-title":"Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children\u2019s Oncology Group phase I consortium report.","volume":"28","author":"Fouladi","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/neuonc\/nov264","article-title":"Atypical teratoid\/rhabdoid tumors-current concepts, advances in biology, and potential future therapies.","volume":"18","author":"Fr\u00fchwald","year":"2016","journal-title":"Neuro Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/1098-2264(2000)9999:9999<::aid-gcc1052>3.0.co;2-s","article-title":"Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs.","volume":"30","author":"Fr\u00fchwald","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1126\/science.1253799","article-title":"Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation.","volume":"346","author":"Funato","year":"2014","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/ijc.22401","article-title":"Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.","volume":"120","author":"Furchert","year":"2007","journal-title":"Int. J. Cancer"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/141793","article-title":"MicroRNA regulation of brain tumour initiating cells in central nervous system tumours.","volume":"2015","author":"Garg","year":"2015","journal-title":"Stem Cells Int."},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-25263-5","article-title":"FTY720 decreases tumorigenesis in group 3 medulloblastoma patient-derived xenografts.","volume":"8","author":"Garner","year":"2018","journal-title":"Sci. Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1179\/1743132815y.0000000048","article-title":"Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.","volume":"37","author":"Geron","year":"2015","journal-title":"Neurol. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins.","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2217\/pgs-2016-0113","article-title":"Pharmacogenomics and histone deacetylase inhibitors.","volume":"17","author":"Goey","year":"2016","journal-title":"Pharmacogenomics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1158\/1078-0432.ccr-05-1225","article-title":"Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.","volume":"12","author":"Graham","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B37","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.semcdb.2013.08.002","article-title":"Retinoids induce stem cell differentiation via epigenetic changes.","volume":"24","author":"Gudas","year":"2013","journal-title":"Semin. Cell Dev. Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/mop.0000000000000562","article-title":"Review of molecular classification and treatment implications of pediatric brain tumors.","volume":"30","author":"Guerreiro Stucklin","year":"2018","journal-title":"Curr. Opin. Pediatr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1038\/onc.2009.161","article-title":"Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.","volume":"28","author":"H\u00e4cker","year":"2009","journal-title":"Oncogene"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1038\/onc.2010.599","article-title":"Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation.","volume":"30","author":"H\u00e4cker","year":"2011","journal-title":"Oncogene"},{"key":"B42","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2176\/nmc.ra.2017-0018","article-title":"Epigenetic targeted therapy for diffuse intrinsic pontine glioma.","volume":"57","author":"Hashizume","year":"2017","journal-title":"Neurol. Med. Chir."},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.3390\/diseases7040057","article-title":"Histone deacetylases and their inhibitors in cancer epigenetics.","volume":"7","author":"Hassell","year":"2019","journal-title":"Diseases"},{"key":"B44","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41417-019-0099-5","article-title":"Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation.","volume":"27","author":"Hellwig","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169485","article-title":"Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models.","volume":"12","author":"Hennika","year":"2017","journal-title":"PLoS One"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030756","article-title":"Analysis of dual class I histone deacetylase and lysine demethylase inhibitor domatinostat (4SC-202) on growth and cellular and genomic landscape of atypical teratoid\/rhabdoid.","volume":"12","author":"Hoffman","year":"2020","journal-title":"Cancers"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4630","article-title":"The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes.","volume":"5","author":"Huether","year":"2014","journal-title":"Nat. Commun."},{"key":"B48","first-page":"6108","article-title":"MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.","volume":"62","author":"Jaboin","year":"2002","journal-title":"Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s12031-020-01505-y","article-title":"HDAC and MAPK\/ERK inhibitors cooperate to reduce viability and stemness in medulloblastoma.","volume":"70","author":"Jaeger","year":"2020","journal-title":"J. Mol. Neurosci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00381-015-2963-4","article-title":"Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists.","volume":"32","author":"Jaeger","year":"2016","journal-title":"Childs Nerv. Syst."},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09981-6","article-title":"PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.","volume":"10","author":"Jain","year":"2019","journal-title":"Nat. Commun."},{"key":"B52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/nan.12616","article-title":"Invited Review: dysregulation of chromatin remodellers in paediatric brain tumours - SMARCB1 and beyond.","volume":"46","author":"Johann","year":"2020","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","article-title":"Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?","volume":"4","author":"Johnstone","year":"2003","journal-title":"Cancer Cell"},{"key":"B54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature11284","article-title":"Dissecting the genomic complexity underlying medulloblastoma.","volume":"488","author":"Jones","year":"2012","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-286","article-title":"The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.","volume":"13","author":"Kerl","year":"2013","journal-title":"BMC Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.mrfmmm.2007.06.005","article-title":"Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells.","volume":"625","author":"Khaw","year":"2007","journal-title":"Mutat. Res."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176855","article-title":"Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma.","volume":"12","author":"Killick-Cole","year":"2017","journal-title":"PLoS One"},{"key":"B58","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer.","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/neuonc\/nor208","article-title":"Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid\/rhabdoid tumor cells.","volume":"14","author":"Knipstein","year":"2012","journal-title":"Neuro Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function.","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"B61","first-page":"465","article-title":"Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma.","volume":"27","author":"Kumar","year":"2007","journal-title":"Anticancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"17335","DOI":"10.1073\/pnas.0706487104","article-title":"Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.","volume":"104","author":"Lahm","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B63","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy.","volume":"27","author":"Lane","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1158\/1078-0432.ccr-11-1921","article-title":"Epigenetic changes in pediatric solid tumors: promising new targets.","volume":"18","author":"Lawlor","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1172\/jci64400","article-title":"A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers.","volume":"122","author":"Lee","year":"2012","journal-title":"J. Clin. Invest."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071455","article-title":"Sonic hedgehog-induced histone deacetylase activation is required for cerebellar granule precursor hyperplasia in medulloblastoma.","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"B67","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-017-0584-0","article-title":"MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours.","volume":"16","author":"Leichter","year":"2017","journal-title":"Mol. Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.29198","article-title":"EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.","volume":"121","author":"Li","year":"2015","journal-title":"Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1158\/1535-7163.mct-05-0184","article-title":"Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC.","volume":"4","author":"Li","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy.","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.conb.2012.04.012","article-title":"Developmental origins of brain tumors.","volume":"22","author":"Liu","year":"2012","journal-title":"Curr. Opin. Neurobiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary.","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1158\/1078-0432.ccr-18-3989","article-title":"Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas.","volume":"25","author":"Lue","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nn.4190","article-title":"An epigenetic gateway to brain tumor cell identity.","volume":"19","author":"Mack","year":"2016","journal-title":"Nat. Neurosci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00381-009-0928-1","article-title":"The genetic and epigenetic basis of ependymoma.","volume":"25","author":"Mack","year":"2009","journal-title":"Childs Nerv. Syst."},{"key":"B76","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature13108","article-title":"Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.","volume":"506","author":"Mack","year":"2014","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbrc.2011.06.141","article-title":"Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.","volume":"411","author":"Marino","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B78","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrc3679","article-title":"The prenatal origins of cancer.","volume":"14","author":"Marshall","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3538","article-title":"Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma.","author":"Meel","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/noz218","article-title":"Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.","volume":"22","author":"Mendez","year":"2020","journal-title":"Neuro Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1200\/jco.2017.73.1265","article-title":"Current clinical challenges in childhood ependymoma: a focused review.","volume":"35","author":"Merchant","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B82","doi-asserted-by":"crossref","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability.","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes"},{"key":"B83","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00401-011-0866-3","article-title":"A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.","volume":"122","author":"Milde","year":"2011","journal-title":"Acta Neuropathol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s11060-012-0978-1","article-title":"HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.","volume":"110","author":"Milde","year":"2012","journal-title":"J. Neurooncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1158\/1078-0432.CCR-10-0395","article-title":"HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.","volume":"16","author":"Milde","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.tips.2016.12.006","article-title":"Targeting class I histone deacetylases in a \u201ccomplex\u201d environment.","volume":"38","author":"Millard","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10637-012-9831-9","article-title":"Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.","volume":"31","author":"Muscal","year":"","journal-title":"Invest. New Drugs"},{"key":"B88","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/pbc.24271","article-title":"A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a children\u2019s oncology group phase I consortium study (ADVL0916).","volume":"60","author":"Muscal","year":"","journal-title":"Pediatr. Blood Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1158\/1078-0432.ccr-15-2260","article-title":"Low-dose histone deacetylase inhibitor treatment leads to tumor growth arrest and multi-lineage differentiation of malignant rhabdoid tumors.","volume":"22","author":"Muscat","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B90","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ccell.2017.03.011","article-title":"Transcriptional dependencies in diffuse intrinsic pontine glioma.","volume":"31","author":"Nagaraja","year":"2017","journal-title":"Cancer Cell"},{"key":"B91","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00381-011-1439-4","article-title":"The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.","volume":"27","author":"N\u00f6r","year":"2011","journal-title":"Childs Nerv. Syst."},{"key":"B92","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s12035-013-8441-7","article-title":"The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells.","volume":"48","author":"N\u00f6r","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ng.336","article-title":"Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma.","volume":"41","author":"Northcott","year":"2009","journal-title":"Nat. Genet."},{"key":"B94","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature11327","article-title":"Subgroup-specific structural variation across 1,000 medulloblastoma genomes.","volume":"488","author":"Northcott","year":"2012","journal-title":"Nature"},{"key":"B95","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/now207","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013.","author":"Ostrom","year":"2016","journal-title":"Neuro Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/neuonc\/noz089","article-title":"A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.","volume":"21","author":"Pak","year":"2019","journal-title":"Neuro Oncol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1158\/0008-5472.can-17-3691","article-title":"Dual HDAC and PI3K inhibition abrogates NF\u03baB- and FOXM1-mediated DNA damage response to radiosensitize pediatric high-grade gliomas.","volume":"78","author":"Pal","year":"2018","journal-title":"Cancer Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3171\/jns.2003.99.3.0534","article-title":"Transcriptional profiling of medulloblastoma in children.","volume":"99","author":"Park","year":"2003","journal-title":"J. Neurosurg."},{"key":"B99","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1126\/science.1198056","article-title":"The genetic landscape of the childhood cancer medulloblastoma.","volume":"331","author":"Parsons","year":"2011","journal-title":"Science"},{"key":"B100","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma.","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"key":"B101","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/08880018.2019.1699213","article-title":"Fingolimod (FTY720) reduces viability and survival and increases histone H3 acetylation in medulloblastoma cells.","volume":"37","author":"Perla","year":"2020","journal-title":"Pediatr. Hematol. Oncol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10555-019-09820-6","article-title":"Aberrantly expressed microRNAs and their implications in childhood central nervous system tumors.","volume":"38","author":"Pezuk","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"B103","doi-asserted-by":"publisher","first-page":"56747","DOI":"10.18632\/oncotarget.18132","article-title":"Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model.","volume":"8","author":"Phi","year":"2017","journal-title":"Oncotarget"},{"key":"B104","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-016-0306-2","article-title":"Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated TET1 expression.","volume":"9","author":"Ramsawhook","year":"2017","journal-title":"Clin. Epigenetics"},{"key":"B105","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12602","article-title":"Epigenetic control of tumor angiogenesis.","volume":"27","author":"Ribatti","year":"2020","journal-title":"Microcirculation"},{"key":"B106","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00280-019-04021-y","article-title":"Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma.","volume":"85","author":"Rodgers","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4103\/abr.abr_142_19","article-title":"Histone deacetylases and histone deacetylase inhibitors: molecular mechanisms of action in various cancers.","volume":"8","author":"Sanaei","year":"2019","journal-title":"Adv. Biomed. Res."},{"key":"B108","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"key":"B109","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1946-x","article-title":"The stem cell-associated transcription co-factor, ZNF521, interacts with GLI1 and GLI2 and enhances the activity of the Sonic hedgehog pathway.","volume":"10","author":"Scicchitano","year":"2019","journal-title":"Cell Death Dis."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s00381-013-2087-7","article-title":"Epigenetic modification after inhibition of IGF-1R signaling in human central nervous system atypical teratoid rhabdoid tumor (AT\/RT).","volume":"29","author":"Shim","year":"2013","journal-title":"Childs Nerv. Syst."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1517\/14728222.2014.938052","article-title":"DNMTs as potential therapeutic targets in high-risk pediatric embryonal brain tumors.","volume":"18","author":"Sin-Chan","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"B112","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3171\/2018.2.PEDS17663","article-title":"The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery.","volume":"22","author":"Singleton","year":"2018","journal-title":"J. Neurosurg. Pediatr."},{"key":"B113","first-page":"755","article-title":"Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.","volume":"28","author":"Sonnemann","year":"2006","journal-title":"Int. J. Oncol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4161\/cbt.19293","article-title":"Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.","volume":"13","author":"Sonnemann","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11060-007-9505-1","article-title":"Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA).","volume":"87","author":"Spiller","year":"2008","journal-title":"J. Neurooncol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00381-012-1965-8","article-title":"Histone deacetylases expression in atypical teratoid rhabdoid tumors.","volume":"29","author":"Sredni","year":"2013","journal-title":"Childs Nerv. Syst."},{"key":"B117","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cell.2007.02.010","article-title":"Genetic and epigenetic regulators of pluripotency.","volume":"128","author":"Surani","year":"2007","journal-title":"Cell"},{"key":"B118","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4161\/cbt.19771","article-title":"Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.","volume":"13","author":"Tang","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"B119","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ccr.2005.09.001","article-title":"Radial glia cells are candidate stem cells of ependymoma.","volume":"8","author":"Taylor","year":"2005","journal-title":"Cancer Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717x-7-52","article-title":"In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model.","volume":"7","author":"Thiemann","year":"2012","journal-title":"Radiat. Oncol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"12129","DOI":"10.1073\/pnas.0505300102","article-title":"Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss.","volume":"102","author":"Tsikitis","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B122","doi-asserted-by":"publisher","first-page":"19519","DOI":"10.1074\/jbc.m114.556555","article-title":"Retinoic acid and histone deacetylases regulate epigenetic changes in embryonic stem cells.","volume":"289","author":"Urvalek","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B123","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1215\/15228517-2006-038","article-title":"Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma.","volume":"9","author":"Vibhakar","year":"2007","journal-title":"Neuro Oncol."},{"key":"B124","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nature09781","article-title":"Cells of origin in cancer.","volume":"469","author":"Visvader","year":"2011","journal-title":"Nature"},{"key":"B125","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ijc.20165","article-title":"Analysis of HIC-1 methylation and transcription in human ependymomas.","volume":"110","author":"Waha","year":"2004","journal-title":"Int. J. Cancer"},{"key":"B126","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.expneurol.2012.11.014","article-title":"The role of stem cells and progenitors in the genesis of medulloblastoma.","volume":"260","author":"Wang","year":"2014","journal-title":"Exp. Neurol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ng.3746","article-title":"SMARCB1-mediated SWI\/SNF complex function is essential for enhancer regulation.","volume":"49","author":"Wang","year":"2017","journal-title":"Nat. Genet."},{"key":"B128","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ijc.23897","article-title":"Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation.","volume":"124","author":"Watanabe","year":"2009","journal-title":"Int. J. Cancer"},{"key":"B129","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1055\/s-0032-1323692","article-title":"Phase I\/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia.","volume":"224","author":"Witt","year":"2012","journal-title":"Klin. Padiatr."},{"key":"B130","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11060-008-9662-x","article-title":"Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma.","volume":"90","author":"Wolff","year":"2008","journal-title":"J. Neurooncol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.","volume":"44","author":"Wu","year":"2012","journal-title":"Nat. Genet."},{"key":"B132","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.","volume":"46","author":"Wu","year":"2014","journal-title":"Nat. Genet."},{"key":"B133","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s13402-017-0319-7","article-title":"Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.","volume":"40","author":"Yuan","year":"2017","journal-title":"Cell. Oncol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41388-019-1036-7","article-title":"EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1\/p53 tumor suppressor pathway.","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"B135","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-019-0153-x","article-title":"A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma.","volume":"8","author":"Zhang","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.43","article-title":"NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations.","volume":"2","author":"Zhao","year":"2014","journal-title":"Pharmacol. Res. Perspect."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00546\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T05:49:46Z","timestamp":1594360186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00546\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":136,"alternative-id":["10.3389\/fcell.2020.00546"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2020.00546","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"article-number":"546"}}